|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:approves
|
gptkb:2020
gptkb:European_Union
gptkb:United_States
|
|
gptkbp:casnumber
|
1394640-80-0
|
|
gptkbp:chemical_formula
|
C22 H24 Cl N5 O2 S
|
|
gptkbp:class
|
tyrosine kinase inhibitor
|
|
gptkbp:clinical_trial
|
Phase 1
LIBRETTO-001
|
|
gptkbp:clinical_use
|
precision medicine
|
|
gptkbp:developed_by
|
gptkb:Loxo_Oncology
|
|
gptkbp:discovery_year
|
gptkb:2017
|
|
gptkbp:dosage_form
|
oral tablet
|
|
gptkbp:drug_interactions
|
CYP3 A4 inducers
CYP3 A4 inhibitors
|
|
gptkbp:formulation
|
gptkb:tablet
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
LOXO-292
|
|
gptkbp:indication
|
gptkb:Oncology
|
|
gptkbp:invention
|
patented
|
|
gptkbp:is_tested_for
|
RET fusion
RET mutation
|
|
gptkbp:marketed_as
|
the brand name Pralsetinib
|
|
gptkbp:mechanism_of_action
|
inhibitor
|
|
gptkbp:project
|
commercialized
|
|
gptkbp:research_areas
|
oncology
|
|
gptkbp:research_institutes
|
gptkb:Duke_University
gptkb:Johns_Hopkins_University
gptkb:Stanford_University
gptkb:University_of_California,_San_Francisco
gptkb:University_of_Chicago
gptkb:University_of_Pennsylvania
gptkb:Massachusetts_General_Hospital
gptkb:Cleveland_Clinic
gptkb:MD_Anderson_Cancer_Center
gptkb:Memorial_Sloan_Kettering_Cancer_Center
|
|
gptkbp:route_of_administration
|
oral
|
|
gptkbp:safety_features
|
generally well tolerated
|
|
gptkbp:service_frequency
|
once daily
|
|
gptkbp:side_effect
|
fatigue
nausea
hypertension
diarrhea
rash
|
|
gptkbp:status
|
approved
|
|
gptkbp:targets
|
RET kinase
|
|
gptkbp:type
|
gptkb:Atom
|
|
gptkbp:used_for
|
treatment of cancer
|
|
gptkbp:weight
|
445.97 g/mol
|
|
gptkbp:bfsParent
|
gptkb:Loxo_Oncology
|
|
gptkbp:bfsLayer
|
5
|